Revolution Medicines Doses First Patient in Phase 1/1b Clinical …
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-doses-first-patient-phase-11b-clinical-0
WebREDWOOD CITY, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-9805, an oral, covalent, mutant-selective KRAS G12D …
DA: 93 PA: 72 MOZ Rank: 53